Abeome and Cato Research to collaborate on ovarian cancer drug

The investment and collaboration will help support continued development of Abeome’s lead ovarian cancer project. Abeome’s proprietary technology improves the development of monoclonal antibodies and Abeome is deploying its technology to provide a shotgun approach to develop an array of antibodies for an ovarian cancer therapeutic target.

Abeome has developed novel monoclonal antibodies to four ovarian cancer cell lines and has begun screening these antibodies in search of those which cause either cancer cell growth inhibition or death.

Joel Eisner, associate principal of Cato BioVentures, said: “We are fascinated with Abeome’s ability to develop such a large library of monoclonal antibodies by use of their technology. They have pushed the bottleneck of therapeutic development to the screening step which will provide a broader selection of novel antibodies to more cancer targets.”